JP2015509714A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015509714A5 JP2015509714A5 JP2014558206A JP2014558206A JP2015509714A5 JP 2015509714 A5 JP2015509714 A5 JP 2015509714A5 JP 2014558206 A JP2014558206 A JP 2014558206A JP 2014558206 A JP2014558206 A JP 2014558206A JP 2015509714 A5 JP2015509714 A5 JP 2015509714A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- chimeric fusion
- fusion polypeptide
- mediated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261601712P | 2012-02-22 | 2012-02-22 | |
| US61/601,712 | 2012-02-22 | ||
| PCT/GB2013/050433 WO2013124666A1 (en) | 2012-02-22 | 2013-02-22 | Tumour necrosis factor receptor fusion proteins and methods of using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015509714A JP2015509714A (ja) | 2015-04-02 |
| JP2015509714A5 true JP2015509714A5 (https=) | 2016-04-14 |
Family
ID=47754861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014558206A Pending JP2015509714A (ja) | 2012-02-22 | 2013-02-22 | 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9731007B2 (https=) |
| EP (1) | EP2817326A1 (https=) |
| JP (1) | JP2015509714A (https=) |
| KR (1) | KR20140135766A (https=) |
| CN (1) | CN104159916A (https=) |
| AU (1) | AU2013223801B2 (https=) |
| CA (1) | CA2865288A1 (https=) |
| HK (1) | HK1201541A1 (https=) |
| NZ (1) | NZ629309A (https=) |
| SG (1) | SG11201405013RA (https=) |
| WO (1) | WO2013124666A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6701079B2 (ja) * | 2013-12-20 | 2020-05-27 | インターベット インターナショナル ベー． フェー． | ヒトｐｄ−１に対するイヌ化マウス抗体 |
| JP2018504911A (ja) * | 2015-01-29 | 2018-02-22 | ネックスヴェット オーストラリア プロプライエタリー リミテッド | 治療及び診断剤 |
| KR20170138426A (ko) * | 2015-03-13 | 2017-12-15 | 삼성바이오에피스 주식회사 | 항-tnf-알파 폴리펩티드 조성물 및 그 용도 |
| CN104840945B (zh) * | 2015-03-25 | 2018-09-07 | 上海市松江区中心医院 | 诱骗受体3在治疗脓毒症药物中的应用 |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| WO2017102920A1 (en) | 2015-12-18 | 2017-06-22 | Intervet International B.V. | Caninized human antibodies to human and canine il-4r alpha |
| WO2017123642A1 (en) * | 2016-01-12 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Methods and uses of osteoclast associated receptor (oscar) for prevention and treatment of osteoarthritis |
| BR112020002871A2 (pt) * | 2017-08-15 | 2020-07-28 | Kindred Biosciences, Inc. | variantes fc de igg para uso veterinário |
| JP2020080784A (ja) * | 2018-11-29 | 2020-06-04 | シスメックス株式会社 | 融合ポリペプチド、融合ポリペプチドの製造方法、及び融合ポリペプチドをコードするｄｎａ |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU640397B2 (en) | 1989-08-25 | 1993-08-26 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulin |
| TWI364458B (en) * | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| AU2006230419A1 (en) * | 2005-03-31 | 2006-10-05 | Targeted Genetics Corporation | Methods for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders |
| EP2725037A1 (en) * | 2008-09-04 | 2014-04-30 | Vet Therapeutics, Inc. | Monoclonal antibodies binding canine CD20 |
| CN101747440B (zh) * | 2008-12-18 | 2014-05-07 | 嘉和生物药业有限公司 | 一种TNFR-Fc融合蛋白及其用途 |
| CN101760506A (zh) * | 2008-12-25 | 2010-06-30 | 欣润(上海)生物药业有限公司 | 一种rhTNFR-Fc融合蛋白生物学活性的检测方法 |
| US8181211B2 (en) | 2009-03-30 | 2012-05-15 | John Mezzalingua Associates, Inc. | Total bandwidth conditioning device |
| WO2010117448A2 (en) * | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| EP2435477A1 (en) * | 2009-05-28 | 2012-04-04 | Glaxo Group Limited | Antigen-binding proteins |
-
2013
- 2013-02-22 EP EP13706693.2A patent/EP2817326A1/en not_active Withdrawn
- 2013-02-22 NZ NZ629309A patent/NZ629309A/en unknown
- 2013-02-22 WO PCT/GB2013/050433 patent/WO2013124666A1/en not_active Ceased
- 2013-02-22 CN CN201380010734.1A patent/CN104159916A/zh active Pending
- 2013-02-22 US US14/380,277 patent/US9731007B2/en active Active
- 2013-02-22 SG SG11201405013RA patent/SG11201405013RA/en unknown
- 2013-02-22 HK HK15102126.6A patent/HK1201541A1/xx unknown
- 2013-02-22 KR KR1020147026150A patent/KR20140135766A/ko not_active Withdrawn
- 2013-02-22 CA CA2865288A patent/CA2865288A1/en not_active Abandoned
- 2013-02-22 JP JP2014558206A patent/JP2015509714A/ja active Pending
- 2013-02-22 AU AU2013223801A patent/AU2013223801B2/en active Active
-
2017
- 2017-07-14 US US15/650,209 patent/US20180153987A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015509714A5 (https=) | ||
| JP2011526792A5 (https=) | ||
| CA3059199C (en) | Antibody fc variants for increased blood half-life | |
| Silacci et al. | Linker length matters, fynomer-Fc fusion with an optimized linker displaying picomolar IL-17A inhibition potency | |
| JP2020531002A5 (https=) | ||
| US20180215805A1 (en) | Therapeutic and diagnostic agents | |
| AU2013211824A1 (en) | Fusion proteins comprising IgG2 hinge domains | |
| AU2018382593B2 (en) | Variants with Fc fragment having an increased affinity for FcRn and an increased affinity for at least one receptor of the Fc fragment | |
| JP7829489B2 (ja) | ヘテロ二量体Ｆｃポリペプチド | |
| AU2013223801B2 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
| JP2020517262A5 (https=) | ||
| Xu et al. | A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A | |
| CN118369334A (zh) | 新型蛋白 | |
| WO2026021622A2 (zh) | 靶向atrn蛋白的抗体或其抗原结合片段及其应用 | |
| TW202246331A (zh) | 人源化補體５ａ受體１抗體及其使用方法 | |
| US20210009674A1 (en) | Bispecific antibodies to tnf-alpha and il-1beta and uses thereof | |
| US20190202908A1 (en) | Bi-specific agents | |
| CN117264054A (zh) | 靶向il-6的纳米抗体、组合物、方法及用途 | |
| CA3088131A1 (en) | Methods and compositions for treating hpa hyperactivity | |
| JP2019516360A (ja) | ヒト化抗ｒａｇｅ抗体 | |
| CN117377688A (zh) | 人源化补体5a受体1抗体和其使用方法 | |
| HK40128818A (zh) | 人源化补体5a受体1抗体和其使用方法 | |
| WO2026072951A2 (en) | Bispecific antibodies that bind tnfrsf25 and αlpha4βeta7 | |
| WO2026072963A1 (en) | Bispecific antibodies that bind tnfrsf25 and il-23/il-23r | |
| WO2023242251A1 (en) | Follistatin-fc fusion proteins |